Forde, Patrick M. http://orcid.org/0000-0001-6925-6344
Anagnostou, Valsamo http://orcid.org/0000-0001-9480-3047
Sun, Zhuoxin
Dahlberg, Suzanne E.
Kindler, Hedy L.
Niknafs, Noushin
Purcell, Thomas
Santana-Davila, Rafael
Dudek, Arkadiusz Z.
Borghaei, Hossein
Lanis, Mara
Belcaid, Zineb
Smith, Kellie N.
Balan, Archana
White, James R.
Cherry, Christopher
Ashok Sivakumar, I. K.
Shao, Xiaoshan M. http://orcid.org/0000-0003-3190-2288
Chan, Hok Yee
Singh, Dipika
Thapa, Sampriti
Illei, Peter B.
Pardoll, Drew M.
Karchin, Rachel http://orcid.org/0000-0002-5069-1239
Velculescu, Victor E. http://orcid.org/0000-0003-1195-438X
Brahmer, Julie R.
Ramalingam, Suresh S. http://orcid.org/0000-0002-0757-3106
Article History
Received: 14 May 2021
Accepted: 15 September 2021
First Online: 8 November 2021
Competing interests
: V.A. receives research funding to her institution from Bristol Myers Squibb and AstraZeneca. P.M.F. has received research funding to his institution from AstraZeneca, Bristol Myers Squibb, Novartis, Corvus and Kyowa. He has also served as a consultant for Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Iteos, Janssen, Mirati, Novartis and Sanofi and as a data and safety monitoring board member for Polaris and Flame Therapeutics. A.D. is Chief Medical Officer and Chief Executive Officer at TTC Oncology, Chief Medical Officer at Luminary Therapeutics, Chief Medical Officer at IGF Oncology, Chief Medical Officer at Squarex and an advisor to the Martell Diagnostic Laboratory. K.N.S. receives research funding to her institution from Bristol Myers Squibb, AstraZeneca and Enara Bio and holds founder’s equity in ManaT Bio. V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, serves on the board of directors and as a consultant for both organizations and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics and Personal Genome Diagnostics. V.E.V. is an inventor of multiple licensed patents related to technologies from Johns Hopkins University. Some of these licenses and relationships are associated with equity or royalty payments directly to Johns Hopkins and V.E.V. V.E.V. is an advisor to Bristol Myers Squibb, Danaher, Genentech and Takeda Pharmaceuticals. Within the last 5 years, V.E.V. has been an advisor to Merck and Ignyta. These arrangements have been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. D.P. is a consultant for Aduro Biotech, Amgen, Bayer, Dynavax, Enara, FLX Bio, Immunomic Therapeutics, Janssen, Merck, Rock Springs Capitol, Tizona and Trieza; is on the Board of Directors of DNAtrix; is on the scientific advisory board of Immununica, WindMil, Dracen, Camden Partners and Astellas; receives research support from Bristol Myers Squibb and Compugen; and is a founder of ManaT Bio. C.C. is the founder of CM Cherry Consulting. J.W. is a consultant for Personal Genome Diagnostics, is the founder and owner of Resphera Biosciences and holds patents, royalties or other intellectual property from Personal Genomic Diagnostics. R.S.-D. is a consultant for Genentech/Roche, Bayer, Bristol Myers Squibb, Eli Lilly, AstraZeneca, NGM Biopharmaceuticals and Takeda Science Foundation. H.B. receives research support from Millennium, Merck, Celgene, Bristol Myers Squibb and Eli Lilly; is on the advisory board and/or a consultant for Bristol Myers Squibb, Eli Lilly, Genentech, Celgene, Pfizer, Merck, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Novartis, Genmab, Regeneron, BioNTech, Cantargia AB, Amgen, Abbvie, Axiom, PharmaMar, Takeda, Huya Bio, Mirati and Daiichi Sankyo; is on the data and safety monitoring board of the University of Pennsylvania, CAR T Program, Takeda and Incyte; is on the scientific advisory board for Sonnetbio (stock options), Rgenix (stock options) and Nucleai (stock options); receives honoraria from Amgen, Pfizer and Daiichi Sankyo; and receives travel support from Amgen, Bristol Myers Squibb, Merck, Eli Lilly, EMD-Serono and Genentech. J.B. is on the advisory board and/or a consultant for Amgen, AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Sanofi and Regeneron; receives grant research funding from AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics and Revolution Medicines; and is on the data and safety monitoring board/committees of GlaxoSmithKline, Sanofi and Janssen. H.L.K. reports personal fees from Aldeyra Therapeutics, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Kyowa, Merck, Paredox Therapeutics, Deciphera, Inhibrx and Inventiva; and non-financial support from AstraZeneca, Boehringer-Ingelheim, Merck, Paredox Therapeutics and Inventiva. H.L.K. also reports funds given to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, Bristol Myers Squibb, Deciphera, GlaxoSmithKline, Eli Lilly, Merck, Polaris, Verastem, Blueprint, Tesaro and Inhibrx. S.R. is a consultant for Amgen, Bristol Myers Squibb, Genentech/Roche, Merck, AstraZeneca, Takeda, Eisai, Daiichi Sankyo, Sanofi, GlaxoSmithKline and Eli Lilly and receives grants from Tesaro, Merck, AstraZeneca, Advaxis, Bristol Myers Squibb, Amgen, Takeda, Genmab and GlaxoSmithKline. All other authors declare no competing interests.